|
Method of treating patients with lichen planus What is described is a method of treating patients suffering from lichen planus, wherein the medicinal products used are 30% sodium thiosulphate 10 ml once a day externally, 0.1% mometasone fuorate; Imunofan is additionally prescribed intramuscularly in a dose of 1.0 ml with the active ingredient arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine 50 mcg every second day; the therapeutic course is 10 days. |
|
Invention relates to the pharmaceutical industry and represents a pharmaceutical composition, possessing neuroprotective, antihypoxic, antiamnestic activity and an ability to increase physical workability, which includes semax and sodium citicoline. |
|
|
Cdc45l peptides and vaccines containing same Present invention refers to immunology. What is presented is a recovered peptide representing a fragment of CDC45L protein and having an ability to induce cytotoxic T-lymphocytes in the form of a complex with HLA-A*2402 or HLA-A*0201 molecule. There are also disclosed a polynucleotide coding the peptide according to the invention; a composition for inducing cytotoxic lymphocyte (CD8-positive T-cell, CTL) in the presence of an antigen-presenting cell (APC); a pharmaceutical composition for treating and/or preventing CDC45L-expressing tumours and/or preventing their postoperative recurrences; methods for inducing APC and CTL; the recovered APC, which represents a complex of HLA-antigen and the peptide according to the invention on its surface; a method for inducing CDC45L-expressing cancer in the individual; an expression vector of the peptide according to the invention and the host cell transformed or transfected thereby; as well as using the peptide according to the invention and APC in producing the pharmaceutical composition for treating or preventing CDC45L-expressing tumours. |
|
Foxm1 peptides and vaccines containing them Present invention refers to immunology. What is presented is a recovered peptide having an ability to induce cytotoxic T-lymphocytes (CTL) in the presence of antigen-presenting cells (APS) carrying HLA-A*2402, and representing a fragment of FOXM1 protein. There are also disclosed: the recovered polynucleotide coding the peptide according to the invention; a composition for CTL induction and a pharmaceutical composition for treating and/or preventing cancer expressing FOXM1, and/or preventing its postoperative recurrences, containing the peptide according to the invention as an agent; methods for APS and CTL induction; the recovered APS having an ability to induce CTL; as well as a method for inducing the immune response to cancer expressing FOXM1 in an individual. |
|
Therapeutic agents for reduction of parathyroid hormone levels Invention relates to compounds, possessing activity, which reduces levels of a parathyroid hormone. The compound contains a peptide and a conjugating group, where the peptide has an amino acid sequence of formula: X1-X2-X3-X4-X5-X6 _X7, in which X1 is D-cysteine; X2 represents an amino acid, selected from a group, consisting of D-arginine and non-cationic amino acid; X3 represents D-arginine; X4 represents an amino acid, selected from a group, consisting of D-arginine and a non-cationic amino acid; X5 represents D-arginine; X6 represents a non-cationic amino acid; X7 represents D-arginine; and where the peptide is bound with the conjugating group by means of a disulphide bond. The compounds can be applied for treating subjects, suffering from, for instance, primary, secondary or tertiary hyperparathyroidism, hypocalcaemia, malignant tumour, metastatic disease of the bone or osteoporosis. |
|
Invention relates to biotechnology, namely, to peptide for stimulation of Hsp70 (heat shock protein 70) or for protection of skin against ultraviolet radiation. Peptide can be represented by peptide with general formula R1-AA1-AA2-AA3-AA4-R2, its stereoisomers, their mixture and/or their cosmetically or pharmaceutically acceptable salt. AA1 represents -His-; AA2 is selected from the group, consisting of -His-, -Leu- and -Pro-; AA3 represents -Leu-; AA4 is selected from the group, consisting of -Arg- and -Asn-. |
|
Peptide having neuroprotective and nootropic activity and pharmaceutical composition based thereon Invention relates to a hexapeptide of formula Thr-Gly-Glu-Asn-His-Arg-NH2, having neuroprotective and nootropic activity. Disclosed novel pharmaceutical composition based on a peptide, which is highly effective in low doses and is used as nasal drops. |
|
Application of mimotopes for treating beta-amyloidoses Group of inventions relates to medicine and deals with the application of at least one peptide, selected from the group, including SEFKHG(C), TLHEFRH(C), ILFRHG(C), TSVFRH(C), SQFRHY(C), LMFRHN(C), SPNQFRH(C), ELFKHHL(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), YEFRHAQ(C) and TEFRHKA(C), for the production of a medication for the prevention and/or treating Alzheimer's disease. The group of inventions relates a vaccine, containing at least one said peptide, intended for the induction of immune response aimed against Aβ. |
|
Pharmaceutical compositions and respective delivery methods Group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition. |
|
Agent and method of treating exudative otitis media in children What is presented is a method of treating exudative otitis media in children with the preparation Imunofan (synthetic hexapeptide with an immunoregulatory action). With underlying conventional treatment using antihistaminic, mucolytic and vasoconstrictive agents, politserisation, ear drum pneumassage, and laser therapy, the immunomodulator Imunofan is introduced intranasally into the children aged 3 to 7 years old according to the schedule: 1 dose (50 mcg) into each nostril 2 times a day daily for 7 days, then 1 dose (50 mcg) into each nostril 1 time a day (at bedtime) daily for 14 days, and further again 1 dose (50 mcg) into each nostril 2 times a day daily for 7 days. |
|
Imp-3 oligopeptides and vaccines containing thereof Invention relates to oligopeptides, containing the sequence NLSSAEVVV (SEQ ID NO:6), in which one or two amino acids can be substituted, possessing the inducibility of cytotoxic T-cells, their pharmaceutical compositions and application for the production of anti-cancer vaccines. |
![Thrombocyte aggregation-inhibiting heteromeric peptides based on imidazo[4,5-e]benzo[1,2-c;3,4-c']difuroxane](http://img.russianpatents.com/img_data/1204/12046126-s.jpg)
|
Thrombocyte aggregation-inhibiting heteromeric peptides based on imidazo[4,5-e]benzo[1,2-c;3,4-c']difuroxane are disclosed: , where R=Phe-Ile-Ala-Asp-Thr; Arg-Tyr-Gly-Asp-Arg; Lys-Ile-Ala-Asp-Asp; His-Ile-Gly-Asp-Asp. |
|
Implanted octreotide delivery device and method for using it Group of inventions refers to medicine and concerns a method for the delivery of octreotide or its pharmaceutically acceptable salt into an individual, involving implanting the implanted device comprising a polyurethane polymer into the individual; the implanted drug delivery device for the octreotide acetate release by diffusion through a polyurethane polymer. |
|
Present invention refers to a peptide, a peptide mimetic or an amino acid derivative, which contain di-substituted β-amino acid, wherein each of substituting group in the β-amino acid, which can be identical or different, contains at least 7 non-hydrogen atoms, is lipophilic and contains at least one cyclic group; one or more cyclic groups in the substituting group can be bound or condensed with one or more numbers of cyclic groups in the other substituting groups, and when the cyclic groups are fused so that an aggregate total number of non-hydrogen atoms for these two substituting groups makes at least 12, wherein the above peptide, peptide mimetic or amino acid derivative consist of 1-4 amino acids or length-equivalent sub-units. |
|
New octapeptide compounds representing somatostatin derivatives Invention refers to biotechnology and medicine. A compound (I) has an affinity to some subtypes of somatostatin receptors, and therefore can be used as a therapeutically active peptide in developing formulations of therapeutic agents for treating pathological conditions or diseases, which involve one or more somatostatin receptors. Besides, the compound (I) can be used as a peptide used as a carrier in prescription formulations. |
|
Method for correction of individual's functional state and performance Invention refers to medicine and can be used for the correction of the individual's functional state and performance. That is ensured by administering Semax neuroactive peptide in a dose of two drops in each nasal passage. That is followed by the electric current exposure covering a frontal-mastoid region at pulse length 0.2ms, current intensity 0.8mA and pulse train 800Hz for 40 min. The exposure is combined with at least 10 sessions of hyperbaric oxygenation at pressure 1.6 atm. |
|
|
Vaccine against intermediate with amyloid coagulation Invention relates to field of biochemistry, in particular to cyclic peptide, capable of inducing antibody response. Peptide consists of formula X2X3VGSNK-Z or X3VGSNKG-Z, where X2 represents E, G, Q or K, X3 represents D or N and Z represents agent, stabilising bent, present inside peptide sequence, with peptide being cyclised by covalent bonding of N-end amino acid with Z, where Z represents peptide fragment YNGK. Conjugate, containing said cyclic peptide, conjugated with immunogenic carrier molecule is also claimed. peptide and conjugate, which contains it, can be applied for production of medication or as vaccine against Alzheimer's disease. Methods of obtaining cyclic peptide and conjugate are also claimed. |
|
Method of treating knee arthritis Treating acute knee arthritis is ensured by measuring a pre-therapeutic blood lymphocyte percentage in the patient. That requires performing 5 sessions of finger point massage of the points IV.9, XI.34, VII.60, III.36. If the lymphocyte percentage is less than 25%, Myelopidum 6 mg a day is administered additionally every second day, in number of 5 injections. |
|
|
Uniform deuterium- or yttrium-labelled his-phe-arg-trp-pro-gly-pro Invention relates to His-Phe-Arg-Trp-Pro-Gly-Pro uniformly labelled with deuterium or yttrium, which can be used in analytical chemistry and biological research. |
|
Claimed invention relates to modified opiorphin peptides as novel inhibitors of metal-ectopeptidases. |
|
Analgesic agent of peptide structure of undercapeptide containing d-octaarginine vector Group concerns using undecapeptide - H-Tyr-Pro-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Gly-OH·9HCl as an analgesic agent. The group of inventions also concerns a dosage form containing the above peptide as an active substance for treating acute and chronic pain syndromes. |
|
Method of increasing human work efficiency Invention relates to sports medicine. Method includes carrying out interval hypoxic training with breathing gas mixture with simultaneous influence on central nervous system by pulse electric current. Before interval hypoxic training additionally realised is introduction of neuropeptide Semax in dose of two drops in each nasal passage. Interval hypoxic training is carried out at least four times by breathing gas mixture, which contains 9.5% of oxygen. Influence by electric current is realised with pulse duration 0.25-0.28 ms, current power 0.9 mA and frequency of pulses 1250 Hz for 60 minutes. |
|
|
Using delta sleep inducing peptide for hepatoprotective effect in chronic immobilisation stress Hepatoprotective effect in a chronic immobilisation stress is ensured by delta sleep inducing peptide having formula (NH2)Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu(COOH). |
|
Invention refers to immunology and biotechnology. Presented is an immunogen for inducing an immune response to the PCSK9 protein, containing the PCSK9 antigen peptide specified in a group consisting of the disclosed SEQ ID NO: 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 314, 318 and 319, containing the amino acid sequence TRFHRQ, and SEQ ID NO: 182, 183, 184, 185, 186, 187, 188, 317, 401, 402 and 403, containing the amino acid sequence SIPWNLE, wherein the above PCSK9 peptide is conjugated with an immunogenic carrier specified in CRM197 or a Qbeta viral-like particle (VLP). Described is a composition for inducing the immune response to the PCSK9 protein containing at least two immunogens in immunologically effective amounts, wherein the first immunogen represents the above immunogen. Disclosed is a composition for inducing the immune response to the PCSK9 protein containing at least two immunogens in the immunologically effective amounts, wherein the first immunogen is specified in a group of immunogens containing the amino acid sequence SIPWNLE, and wherein the second immunogen is specified in a group of immunogens containing the amino acid sequence TRFHRQ; and wherein the composition can additionally contain at least one adjuvant. What is also presented is a pharmaceutical composition for preventing, treating or relieving PCSK9-related disorders containing: the above immunogen in a therapeutically effective amount, or one of the above compositions, and a pharmaceutically acceptable excipient. |
|
Biologically active peptide and methods of using it Group of inventions refers to pharmaceutical industry, particularly to compositions for treating and/or preventing obesity. The composition contains the peptide compound Pro-Val-Asn-Phe-Lys-Phe-Leu-Ser-His in water containing a salt solution in the physiologically acceptable concentration. A therapeutic agent containing the above composition can be presented in the form of spray/drops applicable for nasal, subglossal or oral administration. A dosage form of the nasal or subglossal spray/drops, as well as oral film provides ease of administration and makes it applicable by the patient in need of treating and/or preventing obesity. |
|
|
Method for assessing local humoral anticholeraic immunity in vitro simulated in experimental animals Method involves immunising with 5×107 microbial cells Vibrio cholerae 5879; 10 days later, a common pool of anticholeraic Ig is recovered from enteric washing liquid. That is combined with producing the primary enterocyte culture from intact mice. Thereafter, the doubly-diluted anticholeraic Ig are applied in an amount of 3 ml on a monolayer of erythrocytes formed in wells of culture panels. The latter are added with alive choleraic vibrions of the strain Vibrio cholerae 5879, 40 m.c. per 1 erythrocyte and incubated for 3 hours. Then, the panels are washed three times, fixed with ethanol for 20 minutes and stained by Romanowsky-Giemsa. Local humoral anticholeraic immunity is assessed under the microscope by the number of vibrions stained in dark blue and attached to one erythrocyte. |
|
|
Composition for treating prostate cancer Invention relates to field of pharmaceutics and represents method of treating prostate cancer, which includes introduction to patient of composition, which contains degarelix lyophilisate or its pharmaceutically acceptable salt and excipient, dissolved in solvent, in initial dose 200-300 mg of degarelix in concentration 20-80 mg of degarelix per ml of solvent with the following after 14-56 days after initial dose supporting dose 320-55 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, possibly with one or more than one following additional supporting dose 320-550 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, introduced with interval from 56 days to 112 days between each supporting dose. |
|
Claimed is a vaccine, including a peptide, bound to a pharmaceutically acceptable carrier, which is not angiotensin II and has an amino acid sequence of formula (X1)m(X2)n(X3)oX4X5HPX6, where X1 represents G or D, X2 represents A, P, M, G or R; X3 represents G, A, H or V; X4 represents S, A, D or Y; X5 represents A, D, H, S, N or I; X6 represents A, L or F, where m, n and o independently on each other equals 0 or 1 on condition that when o equals 0, both m and n equal 0, and when n equals 0, m equals 0, and where the peptide is not a peptide DRVYIHPF. The application of such a peptide for the vaccine production is also characterised. |
|
Ttk peptides and vaccines containing them Invention refers to peptide vaccines against cancer. There are presented epitope peptides derived from the TTK gene that elicit CTL development, pharmaceutical compositions containing as active ingredients the above peptides or polynucleotides coding the peptides. |
|
Method of suppressing tumour growth Invention relates to biology and medicine and is aimed at the increase of efficiency of the tumour growth suppression with the application of recombinant human proteins, which bind with a receptor of cytokine TRAIL/Apo2L and trigger apoptotic death of tumour cells, without damaging normal cells. In particular the invention relates to a method of suppressing the tumour growth. The invention consists in the fact that the said recombinant proteins, binding with receptors of cytokine TRAIL/Apo2L, are applied in a combination with substances, which suppress resistance of the tumour cells to TRAIL proteins, and in addition to it cyclic peptide Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys is applied. It is supposed that the said peptide enhances the penetration of TRAIL from the vessels to the tumour cells. |
|
Use of peptide acth (4-7) -pgp of hepatoprotective action Hepatoprotector is used as peptide ACTH (4-7) -PGP (Semax) having the formula Met-Glu-His-Phe-Pro-Gly-Pro. |
|
|
Radiopharmaceutical agent of formula (Ia) or (Ib) , is a cyclic octapeptide complex which contains a chelating group with radionuclides 111In, 90Y, 177Lu. The radiopharmaceutical agent can be used to produce medicinal agents for radionuclide therapy of neoplasms which express somatostatin receptors. X is a chelating agent. |
|
Octreotide-containing composition with delayed release with stably high level of impact Group of inventions relates to field of pharmaceutics and medicine and deals with pharmaceutical composition with delayed release, which contains as active ingredient octreotide or its pharmaceutically acceptable salt and two different linear copolymers of polylactide and glycolide (LCPG), characterised by molar ratios lactide/glycolide 75:25 and different values of viscosity, for prolonged supportive treatment of patients with acromegaly and for treatment of severe forms of diarrhoea and hyperaemia, associated with malignant carcinoid tumours and tumours, cells of which produce vasoactive intestinal peptide. |
|
Application of opiorphin as psychostimulating agent Group of inventions relates to peptides, isolated from human basic proline-rich lacrimal protein (BPLP), in particular to opiorphin, and is intended for application in manufacturing medication for treatment or prevention of such disease as obsessive-compulsive disorder, narcolepsy, hypersomnia, reduction of vigilance, deficit of attention in children, bipolar disease, dysthymic disorder and cyclothymic disorder. |
|
In the process of preoperative preparation imunofan is introduced to a patient intramuscularly in a dose of 1 ml one time per day. After that, laparoscopy with revision of the abdominal cavity organs, opening of the omental bursa and its washing with solutions of antiseptics, and formation of the external cholecystoma are performed. Intraoperatively at the stage of the omental bursa drainage and before performing cholecyctomy, into the stomach introduced is a thin probe for enteral nutrition, through which early intraoperative nutrition is realised by introduction of liquid food "Diason" at a rate of 30 ml/hour in an amount of 450-500 ml on the first day of the postoperative period. In the postoperative period introduction of imunofan in the same dose is continued for 9 days. Introduction of "Diason" food through the thin probe is also continued on the second day of the postoperative period at a rate of 30 ml/hour in an amount of 450-500 ml, on the third day at a rate of 45-60 ml/hour in an amount of 700-750 ml, on 4 and 5 day at a rate of 80-90 ml/hour in an amount of 950-1000 ml, from 6 to 9 days at a rate of 125-150 ml/hour in an amount of 1500-2000 ml. On the 10-th day after operation the probe of enteral nutrition is removed. After that, a seeping type of nutrition is realised, in the process of which a drink supportan or nutridrink is introduced to the patient in an amount of 200 ml 3-4 times per day until complete recovery of the trophological status. |
|
|
Method of treating alzheimer's disease Group of inventions refers to medicine and concerns using a peptide conjugated with a protein representing a keyhole limpet hemocyanin (KLH) protein used as an immunogen for preparing antibodies specifically recognising any of prevailing versions of beta-amyloid peptide Aβ40 and Aβ42; or using an antibody, or an active fragment, or an antibody derivative of the above peptide in preparing a therapeutic agent for preventing and/or treating a disease characterised by amyloid accumulation in the patient's brain. |
|
New peptide and its application Invention relates to a peptide represented by the formula (I) X1-Leu-X2-Leu-X3, where X1 is Glu or Asp, X2 is His, Lys or Arg, X3 is Asp or Glu, at that Glu, Asp, Leu, His, Lys and Arg, or its pharmaceutically acceptable salt and its compositions for treatment or prevention of cartilage damage and/or arthritis. |
|
Compounds have the general formula: X1-X2-X3-Pro-X4-Pro-X5, where X1 is selected from H, Ac-, Palm-; X2 is selected from Trp, Tyr; X3 is selected from Trp, Tyr; X4 is selected from Lys, Orn, Dbu, Dpr, Arg; X5 is selected from-OH, -NH2, -OCH3, -OC2H5, -NH-C6H5. This compound can be represented in the form of retroisomer. |
|
Inhibitors of protease of hepatitis c virus and their application Invention relates to compounds, which can be used as inhibitors of protease of hepatitis C virus, pharmaceutical compositions, containing the said compounds, and methods of their application. |
|
Using somatostatin analogues in meningioma Group of inventions refers to medicine and concerns a method of treating meningioma in an individual in need thereof involving parenteral administration of a therapeutically effective amount of pasireotide or its pharmaceutically acceptable salt into the above individual; a compound for parenteral administration for treating meningioma containing pasireotide or its pharmaceutically acceptable salt together with one or more of their pharmaceutically acceptable solvents or carriers. |
|
Agent for managing alcohol abstinence syndrome Invention refers to medicine, particularly to the addiction pharmacology, and concerns new application of threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-prolyl-diacetate (Selank) as an agent for managing alcohol abstinence syndrome (AAC). It has been stated that Selank eliminates anxiety induced by withdrawal of ethanol. Selank has been detected to recover a threshold of tactile sensation reduced in the period of alcohol withdrawal to the level observed in intact animals. |
|
Application of peptide wnt5-a derivatives for treatment of gastric melanoma and cancer Invention relates to novel non-branched carbamate derivatives of some peptides Wnt-5a, in particular to N-butyloxycarbonyl derivative, their pharmaceutical compositions and their application for treatment of gastric melanoma and cancer. |
|
Inhibitors of protease of hepatitis c virus and their application Invention relates to compounds, which can be used as inhibitors of protease of hepatitis C virus, to pharmaceutical compositions, which contain said compounds, and to methods of their application for treatment of diseases mediated by protease of hepatitis C virus. |
|
Composition for treating pain and/or inflammation Invention relates to application of peptide, which has sequence originating from amino acid sequence of protein SNAP-25, for treatment of pain and/or inflammation. |
|
Epitope wdrpuh peptides and vaccines, containing them Invention relates to peptides, possessing ability to induce cytotoxic T-cells, which contain amino acid sequence from SEQ ID NO: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides, containing said amino acid sequences, in which 1, 2 or several amino acids are substituted and/or added. Claimed invention also relates to medications for treatment or prevention of tumours, with medications containing said peptides. |
|
Novel antibacterial medications for treatment of gram-positive infections Invention relates to novel lipopeptide compound of formula (I) , and to its pharmaceutically acceptable salts, where: R represents: and v represents integer number from 3 to 5. Invention also relates to based on the claimed compound pharmaceutical composition, which possesses antibacterial activity. |
|
Synthetic peptides with non-narcotic type of analgetic action Invention refers to a biotechnology industry, and namely to synthetic peptides having a non-narcotic type of analgetic action of a general formula: 1 H - XDL - L-Leu - D-His - L-Lys - L-Leu - L-Gln - L-Thr - R2 (I), where: H - hydrogen, XDL - absence of amino acid or L-Tyr, R2 - OMe or NH2, as well as peptides - retroinversions of formula (I), which have reverse sequence of amino acids with replacement of L-shape of amino acids with D-shape and D-shape of amino acids with L-shape, with the following general formula: 2 H - D-Thr - D-Gln - D-Leu - D-Lys - L-His - D-Leu - XDL1 - R2 (II), where: H - hydrogen, XDL1 - absence of amino acid or D-Tyr, R2 - OMe or NH2. |
|
Interleukin-15 antagonist peptide Invention relates to molecular pharmacology and particularly to a peptide which is an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound. The invention shows that when bound with an alpha subunit of the receptor (IL-15Rα) the peptide inhibits T cell proliferation induced by IL-15, tumour necrosis factor α (TNFα) induction caused by IL-15, and expression of IL-8 and IL-6 caused by IL-15Rα. The invention also relates to use of the peptide in treating pathologies where anomalous expression of IL-15 or IL-15Rα is associated with the course of a disease such as rheumatoid arthritis (AR) and prostate cancer. |
|
Disclosed is use of a heptapeptide of general formula Tyr-D-Ala-Phe-Gly-Tyr-X-Ser-NH2, where X is D-Pro or Dh-Pro, or Dh-D-Pro, where Dh-Pro is 3,4-dehydroproline, as an antispasmodic, anxiolytic, central anti-inflammatory or anti-alcohol agent. |
|
|
Nonapeptide with antitumour activity Invention refers to peptides or peptide-like molecules of the following formula: CCLLCCLLC (I) (SEQ ID NO: 1) or CLLCCLLCC (III) (SEQ ID NO:3), where C is cationic aminoacid and L is aminoacid with lipophile group R, in which one of the aminoacids, which has lipophile group R, represents genetically uncoded aminoacid. This compound is probably in the form of pharmaceutically acceptable salt, ester or amide, and refers to their use in therapy, and namely as antitumour agents. |
Another patent 2551122.